We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+4.83%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$46B
AUM Growth
+$2.18B
Cap. Flow
+$425M
Cap. Flow %
0.92%
Top 10 Hldgs %
15.17%
Holding
2,954
New
28
Increased
2,252
Reduced
604
Closed
50

Top Buys

Rank Stock Value
1
DD icon
DuPont de Nemours
DD
+$128M
2
BKR icon
Baker Hughes
BKR
+$26.7M
3
IQV icon
IQVIA
IQV
+$14.5M
4
OKE icon
Oneok
OKE
+$14.3M
5
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$11.2M

Sector Composition

Rank Sector Weight
1 Financials 16.64%
2 Technology 15.8%
3 Healthcare 13.57%
4 Industrials 10.87%
5 Consumer Discretionary 9.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNCE
2551
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$302K ﹤0.01%
20,448
+195
+1% +$2.83K
CHFN
2552
DELISTED
Charter Financial Corp
CHFN
$302K ﹤0.01%
16,296
-410
-2% -$7.13K
SMMF
2553
DELISTED
Summit Financial Group, Inc.
SMMF
$301K ﹤0.01%
11,714
+117
+1% +$2.62K
CTO
2554
CTO Realty Growth
CTO
$824M
$300K ﹤0.01%
18,394
+202
+1% +$3.05K
ARD
2555
DELISTED
Ardagh Group S.A. Class A Common Shares
ARD
$300K ﹤0.01%
14,032
-291
-2% -$6.26K
MCBC
2556
DELISTED
Macatawa Bank Corp
MCBC
$299K ﹤0.01%
29,107
+140
+0.5% +$1.33K
PETX
2557
DELISTED
Aratana Therapeutics, Inc.
PETX
$299K ﹤0.01%
48,704
+490
+1% +$3.1K
ODC icon
2558
Oil-Dri
ODC
$1.44B
$295K ﹤0.01%
12,074
WOW
2559
DELISTED
WideOpenWest
WOW
$295K ﹤0.01%
+19,558
New +$318K
BFIN
2560
DELISTED
BankFinancial
BFIN
$294K ﹤0.01%
18,487
-485
-3% -$7.58K
TCMD icon
2561
Tactile Systems Technology
TCMD
$635M
$294K ﹤0.01%
9,515
+165
+2% +$5.22K
ADUS icon
2562
Addus HomeCare
ADUS
$2.16B
$292K ﹤0.01%
8,271
+115
+1% +$4.05K
PSDO
2563
DELISTED
Presidio, Inc. Common Stock
PSDO
$292K ﹤0.01%
20,650
+135
+0.7% +$1.87K
SIGM
2564
DELISTED
Sigma Designs Inc
SIGM
$292K ﹤0.01%
46,342
+320
+0.7% +$1.97K
COLL icon
2565
Collegium Pharmaceutical
COLL
$1.15B
$290K ﹤0.01%
27,633
+230
+0.8% +$2.54K
GDEN
2566
DELISTED
Golden Entertainment
GDEN
$290K ﹤0.01%
11,915
+265
+2% +$5.83K
HOV icon
2567
Hovnanian Enterprises
HOV
$726M
$290K ﹤0.01%
6,003
+58
+1% +$3.1K
RM icon
2568
Regional Management Corp
RM
$301M
$290K ﹤0.01%
11,977
+55
+0.5% +$1.28K
CDXS icon
2569
Codexis
CDXS
$151M
$289K ﹤0.01%
43,422
+550
+1% +$3.04K
ACTG icon
2570
Acacia Research
ACTG
$428M
$288K ﹤0.01%
63,241
+500
+0.8% +$1.87K
FFH
2571
DELISTED
FAIRFAX FINL HLDGS LTD SUB VTG
FFH
$288K ﹤0.01%
+555
New +$288K
CSLT
2572
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$287K ﹤0.01%
66,834
+930
+1% +$3.83K
CNBKA
2573
DELISTED
Century Bancorp Inc/Mass
CNBKA
$287K ﹤0.01%
3,586
-159
-4% -$10.7K
CMRE icon
2574
Costamare
CMRE
$1.88B
$286K ﹤0.01%
46,340
+4,850
+12% +$31.4K
SREV
2575
DELISTED
ServiceSource International, Inc.
SREV
$286K ﹤0.01%
82,581
+310
+0.4% +$1.13K

Similar funds

RhumbLine Advisers's Q3 2017 Portfolio in Review

As of Q3 2017, RhumbLine Advisers held 2,954 positions worth $46B, up 5% from $43.8B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Trading was light in Q3 2017: portfolio turnover was 2.6%. RhumbLine Advisers opened 28 new positions and exited 50, leaving the 2,954-position portfolio largely intact.

By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.

  • RhumbLine Advisers's largest Q3 2017 buy was Baker Hughes: 750,985 shares worth $27.5M.
  • RhumbLine Advisers added most to DuPont de Nemours in Q3 2017, an estimated $128M increase.
  • RhumbLine Advisers's biggest Q3 2017 reduction was UnitedHealth, cutting an estimated $22.8M.
  • RhumbLine Advisers fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $114M.
  • RhumbLine Advisers's ten largest holdings make up 15% of its $46B portfolio in Q3 2017.
  • RhumbLine Advisers opened 28 new positions and closed 50 in Q3 2017.
  • RhumbLine Advisers's portfolio value rose 5% quarter-over-quarter to $46B.

Based on RhumbLine Advisers's 13F filing for Q3 2017, filed 6 Nov 2017.